Table 3.
Vitamin E parameters in the groups of patients treated with DHA-based multivitamin therapy or placebo.
| Parameters | DHA-based multivitamin group (n = 27) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline evaluation (T0) | Follow-up (T1) | |||||||
| Mean ± SD | Median | Interval (Min-Max) | P (vs. Placebo arm T0) | Mean ± SD | Median | Interval (Min–Max) | P (vs. DHA arm T0) | |
| α-TOH(nM) | 18010.2 ± 7873.8 | 15948.1 | 6765.7–36922.8 | 0.37 | 22244.5 ± 8773.4 | 22303.3 | 9795.2–39020.6 | 0.04 |
| α-TOH/Tot lipids (nmol/mg) | 7.08 ± 2.91 | 6.98 | 2.50–13.57 | 0.34 | 8.50 ± 3.29 | 7.93 | 4.71–16.55 | 0.06 |
| α-TOH/Cho (nmol/mg) | 11.49 ± 4.29 | 11.15 | 4.60–20.98 | 0.25 | 14.50 ± 5.84 | 13.87 | 6.59–26.91 | 0.02 |
| α-TOH/TG (nmol/mg) | 21.76 ± 13.74 | 18.54 | 4.48–51.76 | 0.34 | 24.61 ± 13.09 | 22.55 | 8.06–56.33 | 0.23 |
| α-13'-OH (nM) | 14.1 ± 13.5 | 10.0 | 1.7–54.6 | 0.31 | 12.1 ± 12.6 | 7.8 | 3.7–64.9 | 0.30 |
| α-13'-OH (M3 isomer; nM) | 5.1 ± 5.6 | 3.7 | 0.2–26.9 | 0.22 | 3.6 ± 5.4 | 1.8 | 0.3–24.3 | 0.15 |
| α-13′-OH (M3 nM) | 19.1 ± 15.7 | 13.8 | 4.0–63.5 | 0.26 | 15.7 ± 16.7 | 9.8 | 5.2–82.7 | 0.23 |
| α-13'-COOH (nM) | 1.6 ± 0.7 | 1.4 | 0.5–2.7 | 0.38 | 1.6 ± 1.2 | 1.3 | 0.6–5.7 | 0.41 |
| α-CEHC (nM) | 15.6 ± 14.3 | 10.9 | 6.6–66.9 | 0.41 | 35.7 ± 27.7 | 30.3 | 8.1–143.8 | 0.00 |
| γ-TOH (nM) | 584.7 ± 271.3 | 544.3 | 219.2–1218.0 | 0.13 | 455.2 ± 229.2 | 382.7 | 175.3–933.6 | 0.04 |
| γ-TOH/Tot lipids (nmol/mg) | 0.46 ± 0.26 | 0.48 | 0.12–0.99 | 0.38 | 0.38 ± 0.24 | 0.35 | 0.11–1.24 | 0.11 |
| γ-TOH/Cho (nmol/mg) | 0.38 ± 0.17 | 0.38 | 0.11–0.88 | 0.16 | 0.30 ± 0.18 | 0.24 | 0.11–0.84 | 0.07 |
| γ-CEHC (nM) | 147.9 ± 80.2 | 137.2 | 53.0–342.5 | 0.43 | 135.0 ± 74.8 | 108.2 | 41.3–335.6 | 0.28 |
| Parameters | Placebo group (n = 15) | |||||||
| Baseline evaluation (T0) | Follow-up (T1) | |||||||
| Mean ± SD | Median | Interval (Min-Max) | Mean ± SD | Median | Interval (Min-Max) | P (vs. Placebo arm T0) | ||
| α-TOH(nM) | 17114.0 ± 3675.6 | 16901.8 | 11325.9–24933.5 | 17926.6 ± 6595.6 | 16661.9 | 8174.7–32171.3 | 0.37 | |
| α-TOH/Tot lipids (nmol/mg) | 6.64 ± 2.74 | 7.70 | 0.0–9.94 | 8.01 ± 3.44 | 8.00 | 3.49–15.25 | 0.15 | |
| α-TOH/Cho (nmol/mg) | 10.43 ± 4.18 | 11.51 | 0.0–14.79 | 12.17 ± 4.58 | 12.08 | 5.41–22.66 | 0.18 | |
| α-TOH/TG (nmol/mg) | 19.87 ± 9.55 | 21.38 | 0.0–30.25 | 25.58 ± 14.02 | 25.12 | 6.94–48.01 | 0.14 | |
| α-13'-OH (nM) | 11.8 ± 10.3 | 9.3 | 1.7–42.8 | 10.9 ± 6.6 | 10.0 | 1.7–24.6 | 0.40 | |
| α-13'-OH(M3 isomer: nm) | 3.7 ± 3.8 | 2.5 | 0.2–13.8 | 5.8 ± 5.9 | 2.9 | 0.4–19.3 | 0.17 | |
| α-13′-OH + M3 (nM) | 15.6 ± 13.6 | 11.5 | 2.0–56.6 | 16.7 ± 10.4 | 13.9 | 3.8–37.7 | 0.41 | |
| α-13'-COOH (nM) | 1.6 ± 0.9 | 1.8 | 0.2–2.8 | 2.6 ± 1.3 | 2.3 | 1.1–5.0 | 0.03 | |
| α-CEHC (nM) | 14.4 ± 16.0 | 10.9 | 2.6–59.6 | 14.0 ± 8.5 | 10.5 | 5.5–35.2 | 0.47 | |
| γ-TOH (nM) | 485.5 ± 184.9 | 533.0 | 144.6–743.3 | 447.5 ± 133.6 | 438.5 | 239.1–717.8 | 0.28 | |
| γ-TOH/Tot lipids (nmol/mg) | 0.44 ± 0.24 | 0.49 | 0.04–0.74 | 0.46 ± 0.29 | 0.49 | 0.13–1.20 | 0.40 | |
| γ-TOH/Cho (nmol/mg) | 0.32 ± 0.13 | 0.34 | 0.06–0.52 | 0.30 ± 0.09 | 0.30 | 0.14–0.47 | 0.38 | |
| γ-CEHC (nM) | 142.2 ± 118.1 | 92.1 | 34.6–378.2 | 141.6 ± 94.3 | 112.6 | 54.5–333.6 | 0.49 | |
Significant differences were as P values (≤0.05) and are highlighted in bold.